April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Profiling of miRNAs as biomarkers for AMD in human vitreous
Author Affiliations & Notes
  • Catherine Menard
    Polyclinique, Hopital Maisonneuve Rosemont, Montreal, QC, Canada
  • Flavio Rezende
    Polyclinique, Hopital Maisonneuve Rosemont, Montreal, QC, Canada
  • Vincent De Guire
    Polyclinique, Hopital Maisonneuve Rosemont, Montreal, QC, Canada
  • Przemyslaw Sapieha
    Polyclinique, Hopital Maisonneuve Rosemont, Montreal, QC, Canada
  • Footnotes
    Commercial Relationships Catherine Menard, None; Flavio Rezende, None; Vincent De Guire, None; Przemyslaw Sapieha, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1323. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Catherine Menard, Flavio Rezende, Vincent De Guire, Przemyslaw Sapieha; Profiling of miRNAs as biomarkers for AMD in human vitreous. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1323.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Exudative age-related macular degeneration (AMD) represents the leading cause of lost vision in the elderly. Given that the pathology progresses at a slow pace, developing biomarkers is critical. In this regard, early disease detection prior to appearance of symptoms is crucial for rapid intervention and favorable prognosis. Recently, micro RNAs (miRNAs) have been recognized as potent biomarkers for a variety of human diseases including cancers, kidney diseases and acute myocardial infarction. While miRNAs are stable and present in a variety of body fluids including blood and urine, there is currently limited evidence for their presence in vitreous. We therefore decided to investigate in human patients the propensity of vitreal miRNAs to act as biomarkers for exudative AMD.

Methods: In this pilot study, we obtained vitreous from patients suffering from neovascular AMD (n = 4) and non-vascular ocular pathology patients (n = 4). MicroRNA profiles in patient vitreous were obtained through micro-array analysis of 380 miRNAs using TaqMan® Array Human MicroRNA Cards (Applied Biosystems)

Results: Of the 380 miRNAs analyzed, we obtained a significant difference in the expression of seven miRNAs in the vitreous of patients suffering from AMD. We noted an up regulation of miR146 and miR548a in all 4 AMD patients when compared to controls. Conversely, we saw a significant decrease in miRNAs miR16, miR106b, miR205, miR152 and miR24 in patients affected by exudative AMD. In line with a role in disease pathogenesis, miR16 negatively regulates VEGF levels. The observed decrease in miR16 is consistent with elevated VEGF levels in AMD. Confirmation of miRNA expression profiles is now in progress in additional patients.

Conclusions: Our pilot data reveal that miRNAs may be promising biomarkers for the diagnosis of exudative AMD. Currently, patients suffering from AMD are diagnosed at late stages of disease when vision is already compromised. Our data suggests a specific miRNA signature could be obtained in the vitreous of patients suffering from AMD and used to determine onset of treatment. Micro-RNAs are stable RNA molecules that diffuse in circulation and are present in vitreous. The use of miRNAs to predict disease onset may be a potent tool.

Keywords: 412 age-related macular degeneration • 763 vitreous • 695 retinal degenerations: cell biology  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.